SynOx Therapeutics announces $75m Series B round to fund Phase 3 trial of potential best-in-class treatment for TGCT finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Biopharmaceutical company SynOx Therapeutics has raised $75m (€70.5m) to continue its development of a treatment for Tenosynovial Giant Cell Tumour (TGCT).
Dyne Therapeutics, Inc. (NASDAQ:DYN – Get Free Report) traded down 3% on Thursday . The stock traded as low as $27.57 and last traded at $27.89. 552,733 shares were traded during mid-day trading, a decline of 75% from the average session volume of 2,206,098 shares. The stock had previously closed at $28.76. Wall Street Analysts […]
Dyne Therapeutics, Inc. (NASDAQ:DYN – Get Free Report)’s stock price was down 3% during mid-day trading on Thursday . The stock traded as low as $27.57 and last traded at $27.89. Approximately 552,733 shares were traded during trading, a decline of 75% from the average daily volume of 2,206,098 shares. The stock had previously closed […]